Daratumumab, elotuzumab eyed for initial treatment of myelomaMay 4, 2017Lymphoma & Plasma Cell Disorders
Cord blood/placental cell combo induces rapid immune recoveryMay 3, 2017PediatricsLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Ibrutinib monotherapy data in previously treated MZL is availableMay 2, 2017Lymphoma & Plasma Cell Disorders
Pembrolizumab advances in relapsed/refractory classic Hodgkin lymphomaMay 2, 2017Lymphoma & Plasma Cell DisordersImmuno-oncology
Maintenance lenalidomide prolongs progression-free survival in DLBCLApril 30, 2017Lymphoma & Plasma Cell Disorders
In mantle cell lymphoma, triple therapy proves too toxicApril 24, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Prognostic tool may allow tailored therapy for Hodgkin lymphomaApril 21, 2017Lymphoma & Plasma Cell DisordersPediatrics
Newly diagnosed mantle cell lymphoma is ‘one of the hardest consultations’April 21, 2017Lymphoma & Plasma Cell Disorders
Thousands expected to get CAR T-cells by 2018April 20, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Study finds psoriasis link to melanoma and hematologic cancersApril 20, 2017MelanomaLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Obinutuzumab vs. rituximab weighed as follicular lymphoma therapyApril 18, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Expanded drug combinations produce best myeloma inductionApril 14, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
New approach for monitoring minimum residual disease in multiple myelomaMarch 17, 2017Lymphoma & Plasma Cell Disorders
